A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
Neal Van Hoeven(Sana Biotechnology (United States)), Darrick Carter(Infectious Disease Research Institute), Sharvari Waghmare Joshi(Infectious Disease Research Institute), Philip L. Felgner(University of California, Irvine), Sarah Evans(Infectious Disease Research Institute), Christopher B. Fox(Utah State University), Susan L. Baldwin(Seattle Children's Hospital), Nicole L. Marlenee(Colorado State University), Ghislain Ismael Nana(Infectious Disease Research Institute), Mark A. Tomai(3M (United States)), Li Liang(University of Chicago), Rhea N. Coler(Infectious Disease Research Institute), Steven G. Reed(Infectious Disease Research Institute), Tara Evers(Infectious Disease Research Institute), Rie Nakajima(University of California, Irvine), James Elvecrog(3M (United States)), Hong Liang(Infectious Disease Research Institute), Brian Granger(Infectious Disease Research Institute), Airn E. Hartwig(Colorado State University), Susan Lin(Joslin Diabetes Center), Richard A. Bowen(Colorado State University)
Cited by 86
Related Papers
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
|Science|1993|2.3k
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major
|Nature Medicine|2007|1.4k
Key roles of adjuvants in modern vaccines
|Nature Medicine|2013|1.4k
A Two-Amino Acid Change in the Hemagglutinin of the 1918 Influenza Virus Abolishes Transmission
|Science|2007|582
Nomenclature for Synthetic Gene Delivery Systems
|Human Gene Therapy|1997|450